KoBioLabs Balance Sheet Health
Financial Health criteria checks 6/6
KoBioLabs has a total shareholder equity of ₩59.1B and total debt of ₩16.2B, which brings its debt-to-equity ratio to 27.4%. Its total assets and total liabilities are ₩106.3B and ₩47.3B respectively.
Key information
27.4%
Debt to equity ratio
₩16.19b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩57.63b |
| Equity | ₩59.06b |
| Total liabilities | ₩47.28b |
| Total assets | ₩106.34b |
Recent financial health updates
Does KoBioLabs (KOSDAQ:348150) Have A Healthy Balance Sheet?
Sep 06
We're Not Worried About KoBioLabsInc's (KOSDAQ:348150) Cash Burn
Apr 15Recent updates
Take Care Before Diving Into The Deep End On KoBioLabs, Inc (KOSDAQ:348150)
Nov 13Does KoBioLabs (KOSDAQ:348150) Have A Healthy Balance Sheet?
Sep 06Cautious Investors Not Rewarding KoBioLabs, Inc's (KOSDAQ:348150) Performance Completely
Jul 12We're Not Worried About KoBioLabsInc's (KOSDAQ:348150) Cash Burn
Apr 15What Type Of Shareholders Own The Most Number of KoBioLabs,Inc (KOSDAQ:348150) Shares?
Feb 18Financial Position Analysis
Short Term Liabilities: A348150's short term assets (₩69.8B) exceed its short term liabilities (₩15.9B).
Long Term Liabilities: A348150's short term assets (₩69.8B) exceed its long term liabilities (₩31.4B).
Debt to Equity History and Analysis
Debt Level: A348150 has more cash than its total debt.
Reducing Debt: A348150 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A348150 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A348150 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 27.8% each year.